首頁 › 非小細胞肺癌 › 阿肯色 › Springdale
Springdale, AR 的 非小細胞肺癌 臨床試驗
15 項針對 非小細胞肺癌 的研究正在 Springdale（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
招募中2/3 期
- Highlands Oncology Group - Springdale /ID# 277132, Springdale
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
招募中3 期
- Highlands Oncology Group, PA, Springdale
- Highlands Oncology Group, Springdale
- Highlands Oncology Group, PA, Rogers · 距離 10 英里
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
招募中3 期
- Highlands Oncology Group-Research Department ( Site 0062), Springdale
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Highlands Oncology Group, Springdale
- Highlands Oncology Group, Rogers · 距離 10 英里
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
招募中1/2 期
- Highlands Oncology Group, PA, Springdale
- Highlands Oncology Group, PA, Rogers · 距離 10 英里
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
招募中3 期
- Highlands Oncology Group, Springdale
Pan-tumor MRD Study
招募中觀察性研究
- Highlands Oncology Group (HOG), Springdale
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
招募中3 期
- Research Site, Springdale
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
招募中3 期
- Local Institution - 0686, Springdale
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
招募中3 期
- Research Site, Springdale
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
招募中2/3 期
- Highlands Oncology Group - Springdale, Springdale
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- Highlands Oncology Group, Springdale
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
招募中3 期
- Highlands Oncology Group, Springdale
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- Highlands Oncology Group, Springdale
- Highlands Oncology Group, Rogers · 距離 10 英里
BostonGene and Exigent Genomic INsight Study
招募中觀察性研究
- Highlands Oncology Group, Rogers · 距離 10 英里
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Springdale 的其他研究
- 精神分裂症7 項研究
- 肺癌6 項研究
- 轉移性癌症6 項研究
- 大腸直腸癌5 項研究
- 乳癌5 項研究
- 癌症（所有類型）5 項研究
- 重度憂鬱症5 項研究
- 膀胱癌4 項研究
- 憂鬱症4 項研究
- 食道癌3 項研究
- 躁狂症3 項研究
- 頭頸部鱗狀細胞癌3 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。